Literature DB >> 6833231

Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma.

H R Lijnen, M Hoylaerts, D Collen.   

Abstract

Human histidine-rich glycoprotein was found to interact strongly with heparin both in purified systems and in plasma, resulting in neutralization of the anti-coagulant activity of heparin. In purified systems, histidine-rich glycoprotein and heparin react with apparent 1:1 stoichiometry to form a complex with a dissociation constant of 7 nM. Covalent heparin-antithrombin complex still reacts with histidine-rich glycoprotein to form a complex with a dissociation constant of 29 nM. The interaction between a Mr = 4300-heparin fragment and histidine-rich glycoprotein appeared to be more complex. The mechanism of the interaction between histidine-rich glycoprotein and heparin appeared to be different from that between antithrombin III and heparin, since the former is abolished by EDTA and occurs both with heparin molecules having a high affinity or a low affinity for antithrombin III. In plasma, histidine-rich glycoprotein efficiently counteracts the anticoagulant activity of heparin. Both the thrombin times and the activated factor X inhibition following addition of heparin are markedly prolonged in the absence of histidine-rich glycoprotein and shortened by addition of purified histidine-rich glycoprotein. Low affinity heparin was found to efficiently compete with high affinity heparin for binding to histidine-rich glycoprotein but not to antithrombin III. This results in an increased anticoagulant activity of high affinity heparin in the presence of low affinity heparin. Since the effect of histidine-rich glycoprotein on the anticoagulant properties of heparin is clearly demonstrated in normal plasma, it may be of clinical significance.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6833231

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  A rapid quantitative assay for the detection of mammalian heparanase activity.

Authors:  C Freeman; C R Parish
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

2.  Histidine-rich glycoprotein binding to T-cell lines and its effect on T-cell substratum adhesion is strongly potentiated by zinc.

Authors:  H M Olsen; C R Parish; J G Altin
Journal:  Immunology       Date:  1996-06       Impact factor: 7.397

3.  Antibodies to a histidine-rich protein (PfHRP1) disrupt spontaneously formed Plasmodium falciparum erythrocyte rosettes.

Authors:  J Carlson; G Holmquist; D W Taylor; P Perlmann; M Wahlgren
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

4.  Association of purified skeletal-muscle AMP deaminase with a histidine-proline-rich-glycoprotein-like molecule.

Authors:  M Ranieri-Raggi; U Montali; F Ronca; A Sabbatini; P E Brown; A J Moir; A Raggi
Journal:  Biochem J       Date:  1997-09-15       Impact factor: 3.857

5.  Formation, characterization and detection of a ternary complex between S protein, thrombin and antithrombin III in serum.

Authors:  K T Preissner; L Zwicker; G Müller-Berghaus
Journal:  Biochem J       Date:  1987-04-01       Impact factor: 3.857

Review 6.  Revisiting the Pharmacology of Unfractionated Heparin.

Authors:  Abdallah Derbalah; Stephen Duffull; Fiona Newall; Katie Moynihan; Hesham Al-Sallami
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

7.  Complex formation of platelet thrombospondin with histidine-rich glycoprotein.

Authors:  L L Leung; R L Nachman; P C Harpel
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

8.  Complex formation of platelet thrombospondin with plasminogen. Modulation of activation by tissue activator.

Authors:  R L Silverstein; L L Leung; P C Harpel; R L Nachman
Journal:  J Clin Invest       Date:  1984-11       Impact factor: 14.808

Review 9.  [Heparin resistance and antithrombin deficiency].

Authors:  Norbert Maurin
Journal:  Med Klin (Munich)       Date:  2009-06-16

10.  Histidine-rich glycoprotein can prevent development of mouse experimental glioblastoma.

Authors:  Maria Kärrlander; Nanna Lindberg; Tommie Olofsson; Marianne Kastemar; Anna-Karin Olsson; Lene Uhrbom
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.